Portal de Periódicos da CAPES

Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening

2003; Wiley; Volume: 92; Issue: s2 Linguagem: Inglês

10.1111/j.1464-410x.2003.04407.x

1464-410X

Stefano Ciatto, Marco Zappa, Arnauld Villers, Álvaro Páez, Suzie J. Otto, Anssi Auvinen,

Prostate Cancer Diagnosis and Treatment

BJU InternationalVolume 92, Issue s2 p. 97-100 Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening S. Ciatto, S. Ciatto Centro per lo Studio e la Prevenzione Oncologica, Florence, Italy,Search for more papers by this authorM. Zappa, M. Zappa Centro per lo Studio e la Prevenzione Oncologica, Florence, Italy,Search for more papers by this authorA. Villers, A. Villers Urology Departments, Huriez Hospital, Lille, France,Search for more papers by this authorA. Paez, A. Paez University Hospital Getafe, Madrid, Spain,Search for more papers by this authorS.J. Otto, S.J. Otto Department of Public Health, Erasmus University, Rotterdam, the Netherlands,Search for more papers by this authorA. Auvinen, A. Auvinen School of Public Health, Tampere University, FinlandSearch for more papers by this author S. Ciatto, S. Ciatto Centro per lo Studio e la Prevenzione Oncologica, Florence, Italy,Search for more papers by this authorM. Zappa, M. Zappa Centro per lo Studio e la Prevenzione Oncologica, Florence, Italy,Search for more papers by this authorA. Villers, A. Villers Urology Departments, Huriez Hospital, Lille, France,Search for more papers by this authorA. Paez, A. Paez University Hospital Getafe, Madrid, Spain,Search for more papers by this authorS.J. Otto, S.J. Otto Department of Public Health, Erasmus University, Rotterdam, the Netherlands,Search for more papers by this authorA. Auvinen, A. Auvinen School of Public Health, Tampere University, FinlandSearch for more papers by this author First published: 13 January 2004 https://doi.org/10.1111/j.1464-410X.2003.04407.xCitations: 53 S. Ciatto, Department Diagnostic Medical Imaging, CSPO, Viale A. Volta 171, I-50131 Firenze, Italy. e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Auvinen A, Calais Da Silva F, Denis LJ, Hugosson J, Schroeder F. The European Randomised Study for Prostate Cancer (ERSPC). International Cooperation and Preliminary Data. New York: Parthenon, 1996: 167–72 Google Scholar 2 The International Prostate Screening Trial Evaluation Group. Rationale for randomised trials of prostate cancer screening. Eur J Cancer 1999; 35: 262–71 10.1016/S0959-8049(98)00379-7 PubMedWeb of Science®Google Scholar 3 De Koning HJ, Auvinen A, Berenguer-Sanchez A et al. Large-scale randomized prostate cancer screening trials; program performance in the ERSPC and PLCO trials. Int J Cancer 2002; 97: 237–44 10.1002/ijc.1588 CASPubMedWeb of Science®Google Scholar 4 Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980; 14: 29–43 10.3109/00365598009181186 CASPubMedWeb of Science®Google Scholar 5 Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981–90 10.1093/jnci/94.13.981 PubMedWeb of Science®Google Scholar 6 Ciatto S, Zappa M, Bonardi R, Gervasi G. Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screening. Eur J Cancer 2000; 36: 1347–50 10.1016/S0959-8049(00)00119-2 CASPubMedWeb of Science®Google Scholar 7 Advisory Committee on Cancer Prevention. Position paper. Recommendations on cancer screening in European Union. Eur J Cancer 2000; 36: 1473–8 10.1016/S0959-8049(00)00122-2 PubMedGoogle Scholar 8 American Urological Association. Prostate × Specific Antigen (PSA) Best Practice Policy. Oncology 2000; 14: 267–86 PubMedWeb of Science®Google Scholar 9 Melia J, Moss S. Survey of the rate of PSA testing in general practice. Br J Cancer 2001; 85: 656–7 10.1054/bjoc.2001.1962 CASPubMedWeb of Science®Google Scholar 10 Shibata A, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. JNCI 2001; 93: 1109–10 10.1093/jnci/93.14.1109 CASPubMedWeb of Science®Google Scholar 11 Ward JE, Gupta L, Taylor NJ. Do general practitioners use prostate-specific antigen as a screening test for early prostate cancer? Med J Aust 1998; 169: 29–31 10.5694/j.1326-5377.1998.tb141474.x CASPubMedWeb of Science®Google Scholar 12 Fowler FJ, Bin L, Collins MM et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med 1998; 104: 526–32 10.1016/S0002-9343(98)00124-7 PubMedWeb of Science®Google Scholar 13 Legler JM, Feuer EJ, Potosky AL, Merril RM, Kramer BS. The role of prostate specific antigen (PSA) testing pattern in the recent prostate cancer incidence decline in the United States. Cancer Cause Control 1998; 9: 519–27 10.1023/A:1008805718310 CASPubMedWeb of Science®Google Scholar 14 Cooper GS, Yuan Z, Jethva RN, Rimm AA. Determination of county-level prostate carcinoma incidence and detection rates with Medicare claims data. Cancer 2001; 92: 102–9 10.1002/1097-0142(20010701)92:1 3.0.CO;2-I CASPubMedWeb of Science®Google Scholar 15 Pinnock CB, Weller DP, Marshall VR. Self reported prevalence of prostate-specific antigen testing in South Australia: a community study. Med J Aust 1998; 169: 9–10 PubMedWeb of Science®Google Scholar 16 Skovlund E, Fossa SD. PSA analyses in three Norwegian counties in 2000. Tidsskr Nor Laegeforen 1999; 120: 2539–41 PubMedGoogle Scholar 17 Barchielli A, Crocetti E, Zappa M. Has the PSA wave already crashed upon us? Changes in the epidemiology of prostate cancer from 1985 to 1994 in central Italy. Ann Oncol 1995; 3: 361–2 Google Scholar 18 Beemsterboer PM, De Koening HJ, Kranse R, Trienekens PH, Van Der Maas PJ, Schroder FH. Prostate specific antigen testing and digital rectal examinations before and during a randomized study of screening for prostate cancer, Rotterdam. J Urol 2000; 164: 1216–20 10.1016/S0022-5347(05)67144-3 CASPubMedWeb of Science®Google Scholar 19 Otto SJ, Van Der Cruijsen IW, Liem MK et al. Effective PSA contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003; 105: 394–49 10.1002/ijc.11074 CASPubMedWeb of Science®Google Scholar 20 Pàez A, Lujan M, Llanes L et al. PSA use in a Spanish industrial area. Eur Urol 2002; 21: 1–5 Google Scholar 21 Beemsterboer PMM. Evaluation of screening programmes. Studies on Breast Cancer and Prostate Cancer. Doctoral Thesis. 1999 Google Scholar 22 Roos LL, Waida A. Record Linkage Strategies. Part I. estimating information and evaluating approaches. Meth Inform Med 1991; 30: 117–23 CASPubMedWeb of Science®Google Scholar 23 Juusela H, Määttänen L, Tammela T et al. Prostate cancer screening: attitudes and practices among Finnish physicians. In press. Google Scholar 24 Volk RJ, Cass AR. The accuracy of primary care patients' self-reports of prostate-specific antigen testing. Am J Prev Med 2002; 22: 56–8 10.1016/S0749-3797(01)00397-X PubMedWeb of Science®Google Scholar 25 Ciatto S, Bonardi R, Mazzotta A et al. Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate specific antigen. Tumori 1995; 81: 225–9 10.1177/030089169508100401 CASPubMedWeb of Science®Google Scholar 26 De Koning HJ, Liem MK, Baan CA et al. Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial. Int J Cancer 2002; 98: 268–73 10.1002/ijc.10188 CASPubMedWeb of Science®Google Scholar 27 Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1999; 16: 1017–29 10.1002/(SICI)1097-0258(19970515)16:9 3.0.CO;2-V PubMedWeb of Science®Google Scholar Citing Literature Volume92, Issues2December 2003Pages 97-100 ReferencesRelatedInformation